DAVID NELSON to Drug Therapy, Combination
This is a "connection" page, showing publications DAVID NELSON has written about Drug Therapy, Combination.
Connection Strength
0.209
-
All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study. Hepatology. 2015 Apr; 61(4):1127-35.
Score: 0.089
-
The role of ribavirin in direct acting antiviral drug regimens for chronic hepatitis C. Liver Int. 2012 Feb; 32 Suppl 1:103-7.
Score: 0.072
-
A Pragmatic, Randomized Controlled Trial of Oral Antivirals for the Treatment of Chronic Hepatitis C: The PRIORITIZE Study. Hepatology. 2021 12; 74(6):2952-2964.
Score: 0.035
-
Virological response and safety outcomes in therapy-nai ve patients treated for chronic hepatitis C with taribavirin or ribavirin in combination with pegylated interferon alfa-2a: a randomized, phase 2 study. J Hepatol. 2007 Jul; 47(1):51-9.
Score: 0.013